This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Cheng HR, Li XY, Yu HL, Xu M, Zhang YB, Gan SR. Correlation between CCG polymorphisms and CAG repeats during germline transmission in Chinese patients with Huntington’s disease. Neurosci Bull 2020, 36: 811–814.
Yang WQ, Xie JM, Qiang Q, Li L, Lin X, Ren YQ, et al. Gedunin degrades aggregates of mutant huntingtin protein and intranuclear inclusions via the proteasomal pathway in neurons and fibroblasts from patients with Huntington’s disease. Neurosci Bull 2019, 35: 1024–1034.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72: 971–983.
Fu YH, Wu P, Pan YY, Sun XL, Yang HY, Difiglia M, et al. A toxic mutant huntingtin species is resistant to selective autophagy. Nat Chem Biol 2017, 13: 1152–1154.
Ravikumar B, Vacher C, Berger Z, Davies JE, Luo SQ, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004, 36: 585–595.
Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek MM, de Waal RM, Wesseling P, et al. Expression pattern of apoptosis-related markers in Huntington’s disease. Acta Neuropathol 2005, 109: 321–328.
Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 2000, 101: 57–66.
Harper SQ, Staber PD, He XH, Eliason SL, Martins IH, Mao QW, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A 2005, 102: 5820–5825.
Yang S, Chang RB, Yang HM, Zhao T, Hong Y, Kong HE, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Invest 2017, 127: 2719–2724.
Yu M, Fu YH, Liang YJ, Song HK, Yao Y, Wu P, et al. Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington’s disease models. Cell Res 2017, 27: 1441–1465.
Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol 2003, 465: 11–26.
Wang CC, Zhang YF, Guo SM, Zhao Q, Zeng YP, Xie ZC, et al. Correction to GPR52 antagonist reduces huntingtin levels and ameliorates Huntington’s disease-related phenotypes. J Med Chem 2021, 64: 1220–1221.
Wen X, An P, Li HX, Zhou ZJ, Sun YM, Wang J, et al. Tau accumulation via reduced autophagy mediates GGGGCC repeat expansion-induced neurodegeneration in Drosophila model of ALS. Neurosci Bull 2020, 36: 1414–1428.
Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011, 29: 1046–1051.
Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 2014, 112: 24–49.
We thank Drs Lixiang Ma and Saiyin Hexige for sharing the HD iPSC lines. This work was supported by the National Natural Science Foundation of China (31970748, 92049301, and 81870990) and the Research Start-up Fund of Fudan University, China.
Conflict of interest
The authors claim no conflicts of interest.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Zhang, X., Wen, X., Al-Ramahi, I. et al. Inhibition of HIPK3 by AST487 Ameliorates Mutant HTT-Induced Neurotoxicity and Apoptosis via Enhanced Autophagy. Neurosci. Bull. (2021). https://doi.org/10.1007/s12264-021-00783-9